Table 3.
Caucasians/Hispanics (base-case ICER of universal HLA-B*5801 testing $183,720) | African Americans (base-case ICER of universal HLA-B*5801 testing $83,450) | Asians (base-case ICER of universal HLA-B*5801 testing $64,190) | ||||
---|---|---|---|---|---|---|
Test Characteristics and Probability and Complications of SJS/TEN (base-case; low range, high range) | ||||||
Sensitivity (0.8417; 0.74 , 1.00) | $201,790 | $158,930 | $91,800 | $71,930 | $70,680 | $55,150 |
Specificity (0.9538; 0.85 , 1.00) | $187,250 | $182,420 | $85,080 | $82,850 | $65,470 | $63,720 |
Death due to SJS/TEN (0.30; 0.15 , 0.45) | $261,170 | $124,030 | $117,470 | $65,040 | $91,310 | $49,840 |
Probability of SJS/TEN (Caucasians and Hispanics: 0.00026; 0.00013 , 0.00039) (African Americans: 0.00136; 0.00068 , 0.00204) (Asians: 0.00298; 0.00149 , 0.00447) | $298,140 | $131,080 | $137,330 | $57,820 | $109,030 | $43,400 |
Long Term Complications from SJS/TEN (0.19; 0.10 , 0.29) | $192,580 | $175,600 | $87,630 | $79,620 | $67,610 | $61,070 |
Utility (base-case; low range, high range) | ||||||
SJS/TEN (0.35; 0.22 , 0.48) | $183,490 | $183,900 | $83,350 | $83,550 | $64,110 | $64,270 |
Other Hospitalized Cutaneous Adverse Reactions (0.53; 0.27 , 0.68) | $183,660 | $183,750 | $83,420 | $83,470 | $64,170 | $64,200 |
Long Term Complications from SJS/TEN (0.68; 0.57 , 0.79) | $177,950 | $189,870 | $80,850 | $86,220 | $62,130 | $66,390 |
Cost (base-case; low range, high range) | ||||||
SJS/TEN ($45,661; $22,830 , $68,491) | $187,400 | $180,030 | $87,100 | $79,800 | $67,970 | $60,410 |
Other Hospitalized Cutaneous Adverse Reactions ($6,180; $3,090 , $9,270) | $183,780 | $183,650 | $83,520 | $83,380 | $64,260 | $64,120 |
Long Term Complications SJS/TEN ($980; $945 , $1,012) | $183,740 | $183,710 | $83,470 | $83,440 | $64,210 | $64,180 |
Allopurinol ($72; $35 , $107) | $184,780 | $182,730 | $84,540 | $82,440 | $65,170 | $63,280 |
Febuxostat ($2,213; $1,111 , $3,336) | $149,880 | $218,350 | $48,780 | $118,930 | $32,800 | $96,320 |
Abbreviations: ICER, incremental costeffectiveness ratio; SJS, Stevens-Johnson Syndrome; TEN, Toxic Epidermal Necrolysis